{"product_id":"biolegend-108908","title":"Biolegend, 108908, PE anti-mouse CD49b (pan-NK cells) Antibody, 200μg","description":"\u003cp\u003eDX5 antigen has been recently characterized as CD49b. It is a 150 kD integrin α chain also known as α 2 integrin, VLA-2 α chain, and integrin α 2 chain. CD49b non-covalently associates with CD29 (β 1 integrin) to form the CD49b\/CD29 complex known as VLA-2, a receptor for collagen and laminin. CD49b is expressed on platelets, the majority of NK cells, NKT cells, and a small subset of CD8+ T cells (this population can be significantly increased following viral infection). DX5 is used for the identification and isolation of NK cells, and is especially useful for identifying NK cells in mice lacking the NK1.1 antigen.\u003cbr\u003e\n200μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: IL-2-propagated NK1.1+ cells from C57BL\/6 mice\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen in vitro. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity2 and immunohistochemical staining5 of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections10. The binding of DX5 antibody to splenic NK cells can be blocked by HMa2 antibody.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Arase H, et al. 2001. J. Immunol. 167:1141. (FC) Sepulveda H, et al. 1999. J. Immunol. 163:1133. Norian LA and Allen PM. 2004. J. Immunol. 173:835. (FC) Andoniou CE, et al. 2005. Nature Immunology 6:1011. Oertelt S, et al. 2006. J. Immunol. 177:1655. (IHC) PubMed Bourdeau A, et al. 2007. Blood doi:10.1182\/blood-2006-08-044370. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Qui Q, et al. 2010. J. Immunol. 184:1681. (FC) PubMed Busche A, et al. 2011. J. Immunol. 186:2918. PubMed Kim HR, et al. 2011. Nephrology 16:545. (IHC) PubMed Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed Younos IH, et al. 2012. Int Immunopharmacol. 13:245. PubMed Honjo K, et al. 2012. PNAS. PubMed. Huang HN, et al. 2013. Biomaterials. 34:10151. PubMed\u003cbr\u003e\nProduct Citations: Glasner A,et al. 2017. Sci Rep.. 10.1038\/s41598-017-12998-w. PubMed Fu S, et al. 2023. Nat Commun. 14:2248. PubMed Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed Goncharov NV, et al. 2022. J Evol Biochem Physiol. 58:230. PubMed Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed Nautiyal J, et al. 2013. Development. 140:1079. PubMed Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed Lu H, et al. 2021. Autophagy. 17:2511. PubMed Currier MA, et al. 2017. Oncotarget. 8:17412. PubMed Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941. PubMed Sugimoto C, et al. 2022. Elife. 11:. PubMed Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed Li J, et al. 2019. JCI Insight. 5. PubMed Steven A, et al. 2013. Mol Cancer Res. 11:1462. PubMed Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed Vettorazzi S, et al. 2015. Nat Commun. 6: 7796. PubMed Textor A, et al. 2014. Cancer Res. 74:6769. PubMed Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed Sauma D, et al. 2017. Immunol Res. 10.1007\/s12026-017-8936-9. PubMed Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed Nakamura K, et al. 2013. Proc Natl Acad Sci U S A. 110:9421. PubMed Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed Furuya Y, et al. 2013. Infect Immun . 81:3434. PubMed Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed Sinha S, et al. 2012. J Leukoc Biol. 92:713. PubMed Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed Fan X, et al. 2014. PLoS One. 9:107638. PubMed\u003cbr\u003e\nRRID: AB_313414 (BioLegend Cat. No. 108907) AB_313415 (BioLegend Cat. No. 108908)\u003cbr\u003e\nStructure: Integrin α chain, 150 kD\u003cbr\u003e\nDistribution: NK cells, subset of T cells\u003cbr\u003e\nFunction: Adhesion\u003cbr\u003e\nLigand\/Receptor: Collagen, laminin\u003cbr\u003e\nCell Type: NK cells, T cells\u003cbr\u003e\nBiology Area: Cell Adhesion, Cell Biology, Immunology, Innate Immunity\u003cbr\u003e\nMolecular Family: Adhesion Molecules, CD Molecules\u003cbr\u003e\nAntigen References: 1. Arase H, et al. 2001. J. Immunol. 167:1141. 2. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 3. Sasaki K, et al. 2003. Int. Immunol. 15:701. 4. Inoue O, et al. 2003. J. Cell Biol. 160:769.\u003cbr\u003e\nGene ID: 16398\u003cbr\u003e\nUniProt: View information about CD49b on UniProt.org\u003cbr\u003e\nClone: DX5\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: α2 integrin, VLA-2 α chain, DX5, Integrin α2 chain, ITGA2\u003cbr\u003e\nIsotype: Rat IgM, κ\u003cbr\u003e\nQ: What type of PE do you use in your conjugates?\u003cbr\u003e\nA: We use R-PE in our conjugates.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863062401193,"sku":"108908","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-108908","provider":"Iright","version":"1.0","type":"link"}